MannKind Corp. (MNKD)
4.09
+0.02
(+0.49%)
USD |
NASDAQ |
Nov 18, 14:16
MannKind Enterprise Value : 1.648B for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 1.648B |
| November 16, 2026 | 1.611B |
| November 13, 2026 | 1.667B |
| November 12, 2026 | 1.677B |
| November 11, 2026 | 1.687B |
| November 10, 2026 | 1.699B |
| November 09, 2026 | 1.687B |
| November 06, 2026 | 1.593B |
| November 05, 2026 | 1.548B |
| November 04, 2026 | 1.603B |
| November 03, 2026 | 1.539B |
| November 02, 2026 | 1.513B |
| October 30, 2026 | 1.465B |
| October 29, 2026 | 1.465B |
| October 28, 2026 | 1.442B |
| October 27, 2026 | 1.397B |
| October 26, 2026 | 1.378B |
| October 23, 2026 | 1.365B |
| October 22, 2026 | 1.368B |
| October 21, 2026 | 1.320B |
| October 20, 2026 | 1.336B |
| October 19, 2026 | 1.333B |
| October 16, 2026 | 1.317B |
| October 15, 2026 | 1.365B |
| October 14, 2026 | 1.310B |
| Date | Value |
|---|---|
| October 13, 2026 | 1.320B |
| October 12, 2026 | 1.346B |
| October 09, 2026 | 1.397B |
| October 08, 2026 | 1.439B |
| October 07, 2026 | 1.449B |
| October 06, 2026 | 1.532B |
| October 05, 2026 | 1.568B |
| October 02, 2026 | 1.561B |
| October 01, 2026 | 1.609B |
| September 30, 2026 | 1.593B |
| September 29, 2026 | 1.360B |
| September 28, 2026 | 1.363B |
| September 25, 2026 | 1.360B |
| September 24, 2026 | 1.345B |
| September 23, 2026 | 1.360B |
| September 22, 2026 | 1.407B |
| September 21, 2026 | 1.410B |
| September 18, 2026 | 1.422B |
| September 17, 2026 | 1.435B |
| September 16, 2026 | 1.425B |
| September 15, 2026 | 1.429B |
| September 14, 2026 | 1.487B |
| September 11, 2026 | 1.487B |
| September 10, 2026 | 1.500B |
| September 09, 2026 | 1.546B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| United Therapeutics Corp. | 22.69B |
| ACADIA Pharmaceuticals, Inc. | 2.261B |
| Alnylam Pharmaceuticals, Inc. | 20.36B |
| Anika Therapeutics, Inc. | 153.30M |
| Savara, Inc. | 821.52M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.22M |
| Revenue (Quarterly) | 101.87M |
| Total Expenses (Quarterly) | 125.09M |
| EPS Diluted (Quarterly) | -0.0725 |
| Gross Profit Margin (Quarterly) | 71.85% |
| Profit Margin (Quarterly) | -22.80% |
| Earnings Yield | -5.87% |
| Normalized Earnings Yield | -5.049 |